Kulkarni Santosh S, Grundt Peter, Kopajtic Theresa, Katz Jonathan L, Newman Amy Hauck
Medicinal Chemistry Section, National Institute on Drug Abuse--Intramural Research Program, National Institutes of Health, 5500 Nathan Shock Drive, Baltimore, Maryland 21224, USA.
J Med Chem. 2004 Jun 17;47(13):3388-98. doi: 10.1021/jm030646c.
The development of structure-activity relationships (SAR) with divergent classes of monoamine transporter ligands and comparison of their effects in animal models of cocaine abuse have provided insight into the complex relationship among structure, binding profiles, and behavioral activity. Many 3alpha-(diphenylmethoxy)tropane (benztropine) analogues are potent dopamine uptake inhibitors but exhibit behavioral profiles that differ from those of cocaine and other compounds in this class. One of the most potent and dopamine transporter (DAT) selective N-substituted benztropine analogues (N-(4-phenyl-n-butyl)-3alpha-(bis[4-fluorophenyl]methoxy)tropane, 1c) is devoid of cocaine-like behaviors in rodent models but is also highly lipophilic (cLogD = 5.01), which compromises its water solubility and may adversely affect its pharmacokinetic properties. To further explore the SAR in this series and ultimately to design dopamine uptake inhibitors with favorable lipophilicities for drug development, a comparative molecular field analysis (CoMFA) was performed on a set of benztropine analogues previously synthesized in our laboratory. The CoMFA field analysis on the statistically significant (r2(cv) = 0.632; r2(ncv) = 0.917) models provided valuable insight into the structural features required for optimal binding to the DAT, which was used to design a series of novel benztropine analogues with heteroatom substitutions at the tropane N-8. These compounds were evaluated for binding at DAT, serotonin (SERT) and norepinephrine (NET) transporters, and muscarinic M1 receptors in rat brain. Inhibition of [3H]DA uptake in synaptosomes was also evaluated. Most of the analogues showed high DAT affinity (12-50 nM), selectivity (10- to 120-fold), potent inhibition of dopamine uptake, and lower lipophilicities as predicted by cLogD values.
通过对不同类别的单胺转运体配体进行构效关系(SAR)研究,并比较它们在可卡因滥用动物模型中的作用,有助于深入了解结构、结合谱和行为活性之间的复杂关系。许多3α-(二苯基甲氧基)托烷(苯海索)类似物是有效的多巴胺摄取抑制剂,但其行为特征与可卡因及该类中的其他化合物不同。最有效且对多巴胺转运体(DAT)具有选择性的N-取代苯海索类似物之一(N-(4-苯基正丁基)-3α-(双[4-氟苯基]甲氧基)托烷,1c)在啮齿动物模型中没有可卡因样行为,但脂溶性也很高(cLogD = 5.01),这会影响其水溶性,并可能对其药代动力学性质产生不利影响。为了进一步探索该系列中的构效关系,并最终设计出具有良好脂溶性以用于药物开发的多巴胺摄取抑制剂,我们对先前在我们实验室合成的一组苯海索类似物进行了比较分子场分析(CoMFA)。对具有统计学意义(交叉验证相关系数r2(cv) = 0.632;非交叉验证相关系数r2(ncv) = 0.917)的模型进行的CoMFA场分析,为最佳结合DAT所需的结构特征提供了有价值的见解,该见解被用于设计一系列在托烷N-8位具有杂原子取代的新型苯海索类似物。对这些化合物在大鼠脑中与DAT、5-羟色胺(SERT)、去甲肾上腺素(NET)转运体以及毒蕈碱M1受体的结合情况进行了评估。还评估了它们对突触体中[3H]多巴胺摄取的抑制作用。大多数类似物显示出高DAT亲和力(12 - 50 nM)、选择性(10至120倍)、对多巴胺摄取的有效抑制作用,并且根据cLogD值预测其脂溶性较低。